MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Lesokhin, A. M.; Raza, M. S.; Acosta, J.; Muller, P.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.; Service, M. |
| Abstract Title: | MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406354 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.11003 |
| Notes: | Meeting Abstract: TPS7577 -- Source: Wos |
